Cannabinoid Receptors



24 Item(s)

per page

Set Descending Direction
Catalog No. Product Name Application Product Information
A14170

JWH 307

cannabinoid agonist
JWH 307 is a (1-naphthoyl)pyrrole cannabimimetic that potently activates both central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors (Ki values of 7.7 and 3.3 nM, respectively).
A14169

JWH 249

-
JWH 249 is a synthetic cannabinoid (CB) that potently activates the central CB1 and peripheral CB2 receptors (Ki = 8.4 and 20 nM, respectively).
A14168

JWH 018

CB2 agonist
JWH 018 is a mildly selective agonist of the peripheral cannabinoid (CB2) receptor, derived from the aminoalkylindole WIN 55,212-2
A14167

JWH 073

-
JWH 073 is a mildly selective agonist of the central cannabinoid (CB1) receptor derived from the aminoalkylindole WIN 55,212-2. The Ki values for binding CB1 and the peripheral cannabinoid (CB2) receptor are 8.9 and 38 nM, respectively for a CB1:CB2 ratio of 0.23
A14166

JWH 370

-
JWH 370 is a (1-naphthoyl)pyrrole analog of JWH 018 that potently activates both CB1 and CB2 receptors (Ki values of 5.6 and 4.0 nM, respectively)
A14165

JWH 250

-
JWH 250 is a cannabimimetic indole that shows a high-affinity for both the central cannabinoid (CB1) and the peripheral cannabinoid (CB2) receptors
A12914 SALE

AM251

CB1 receptor antagonist
AM251 is a potent CB1 receptor antagonist (IC50 = 8 nM, Ki = 7.49 nM) that displays 306-fold selectivity over CB2 receptors.
A14174

AM 2201

Cannabinoid inhibitor
AM2201 is a potent synthetic cannabinoid (CB) with Ki values of 1.0 and 2.6 nM for the CB1 and CB2 receptors, respectively
A14189

Tedalinab

CB2 receptor agonist
Tedalinab (GRC-10693) is a drug developed for the treatment of osteoarthritis and neuropathic pain, which acts as a potent and selective cannabinoid CB2 receptor agonist. It has a very high selectivity of 4700x for CB2 over the related CB1 receptor, has good oral bioavailability and has shown promising safety results and effective analgesic and antiinflammatory actions in early clinical trials.
A14110

PB-22

-
PB-22 is an analog of JWH 018 which differs by having 8-hydroxyquinoline replacing the naphthalene group of JWH 018.
A15200 SALE

Otenabant

CB1 receptor antagonist
Otenabant is a recently discovered selective, high affinity, competitive CB1 receptor antagonist with Ki of 0.7 nM.
A14993 SALE

AM630

CB2 antagonist
AM630 is a selectivity CB2 antagonist with Ki of 31.2 nM, > 150 fold selectivity over CB1 receptor.
A16328

Bay 59-3074

CB1/CB2 receptor agonist
Bay 59-3074 is a novel, selective CB1/CB2 receptor partial agonist with Ki values of 48.3 and 45.5 nM at human CB1 and CB2 receptors respectively .
A11513

Org 27569

CB1 modulator‎
Org 27569 is a potent CB1 receptor allosteric modulator (pEC50 = 8.24).
A12849 SALE

AB-FUBINACA

-
AB-FUBINACA was first synthesized by Pfizer as a potent CB1 receptor modulator for potential therapeutic use, but recently was identified along with AB-PINACA (Item No. 14038) in illegal herbal products.
A11547 SALE

Rimonabant (SR141716)

-
Rimonabant is a selective antagonist of CB1 with IC50 of 13.6 nM and EC50 of 17.3 nM in hCB1 transfected HEK 293 membrane.
A11780 SALE

JWH 133

CB2 agonist
JWH-133 is a potent selective CB2 receptor agonist, with a Ki of 3.4nM and selectivity of around 200x for CB2 over CB1 receptors.
A11253

GW842166X

CB2 receptor agonist
GW842166X is a selective non-cannabinoid CB2 receptor agonist, which is undergoing clinical development as a novel oral treatment for inflammatory pain
A11942

CP 945598 HCl

CB1 antagonist
CP 945598 is a potent and highly selective CB1 antagonist.
A11939

MDA 19

CB2 agonist
MDA 19 is a potent and selective agonist for the cannabinoid receptor CB2, with reasonable selectivity over the psychoactive CB1 receptor.
A11938

BML-190

CB2 receptor ligand
BML-190 is a selective inverse agonist of the human cannabinoid CB2 receptor.
A11932 SALE

WIN 55,212-2 mesylate

CB receptor agonist
WIN 55,212-2 is a potent cannabinoid receptor agonist that has been found to be a potent analgesic in a rat model of neuropathic pain. It activates p42 and p44 MAP kinase via receptor-mediated signaling.
A11096 SALE

UR-144

-
UR-144 is a potent synthetic cannabinoid (CB) which preferentially binds the peripheral CB2 receptor (Ki = 1.8 nM) over the central CB1 receptor (Ki = 150 nM).
A16397

AM1241

CB2 receptor agonist
AM1241 is a selective cannabinoid CB2 receptor agonist with Ki of 3.4 nM, exhibits 82-fold selectivity over CB1 receptor.

24 Item(s)

per page

Set Descending Direction